Compare CMPR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | NVAX |
|---|---|---|
| Founded | 1994 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2005 | 1996 |
| Metric | CMPR | NVAX |
|---|---|---|
| Price | $71.20 | $9.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $86.50 | $11.33 |
| AVG Volume (30 Days) | 85.4K | ★ 4.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | 2.26 | ★ 2.58 |
| Revenue | ★ $3,403,079,000.00 | $1,123,479,000.00 |
| Revenue This Year | $10.43 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | $30.92 | ★ $3.89 |
| Revenue Growth | 3.38 | ★ 64.69 |
| 52 Week Low | $35.28 | $5.01 |
| 52 Week High | $82.43 | $11.85 |
| Indicator | CMPR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 49.52 |
| Support Level | $69.03 | $7.81 |
| Resistance Level | $75.75 | $10.42 |
| Average True Range (ATR) | 2.69 | 0.60 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 59.16 | 30.92 |
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.